7 completed, 4 terminated, 1 recruiting, 1 withdrawn. 10 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Terminated 3, Recruiting 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 3, Terminated 2 |
Follow reparixin: new trials by email Literature Review of reparixin trials Research Report on reparixin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) reparixin - Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 10 | 2023-07-24 | 2026-05-06 |
| Add-on Reparixin in Adult Patients With ARDS Reparixin 600mg, Matching Placebo - Acute Respiratory Distress Syndrome, Adult | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 66 | 2022-12-06 | 2026-05-11 |
| Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Reparixin, Placebo - Infectious Pneumonia, Severe COVID-19 | Phase 3 | Terminated | Dompé Farmaceutici S.p.A | 414 | 2022-04-27 | 2026-02-24 |
| To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer Reparixin, Placebo - Fatigue, Locally Advanced or Metastatic Breast Cancer | Phase 2 | Withdrawn | Dompé Farmaceutici S.p.A | 2022-04-19 | 2024-04-30 | |
| Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. Reparixin, Placebo - Pneumonia, Viral | Phase 3 | Completed | Dompé Farmaceutici S.p.A | 287 | 2021-02-14 | 2024-06-13 |
| Reparixin in COVID-19 Pneumonia - Efficacy and Safety Reparixin, Standard of care - Severe Pneumonia | Phase 2 / Phase 3 | Terminated | Dompé Farmaceutici S.p.A | 56 | 2020-05-05 | 2024-01-08 |
| A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer paclitaxel, Reparixin, placebo - Metastatic Breast Cancer | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 194 | 2015-07-29 | 2022-09-16 |
| Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation Reparixin, Control - Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction | Phase 2 | Terminated | Dompé Farmaceutici S.p.A | 40 | 2015-03-10 | 2025-01-07 |
| Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation Reparixin, Placebo - Pancreatectomy for Chronic Pancreatitis | Phase 2 / Phase 3 | Completed | Dompé Farmaceutici S.p.A | 104 | 2014-02-01 | 2023-11-02 |
| Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer Reparixin - Breast Cancer | Phase 2 | Terminated | Dompé Farmaceutici S.p.A | 20 | 2013-02-01 | 2021-05-14 |
| Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation Reparixin, Placebo - Islet Transplantation in Diabetes Mellitus Type 1 | Phase 3 | Completed | Dompé Farmaceutici S.p.A | 51 | 2012-10-01 | 2024-01-03 |
| Reparixin in Pancreatic Islet Transplantation Reparixin - Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 9 | 2010-07-28 | 2021-03-11 |
| Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation Repertaxin, Placebo - Ischemia-Reperfusion Injury, Lung Transplantation | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 114 | 2005-05-01 | 2024-12-11 |
Breast Neoplasms (3) · COVID-19 (3) · Diabetes Mellitus, Type 1 (2) · Pneumonia (2) · Reperfusion Injury (2) · Fatigue (1) · Pneumonia, Viral (1) · Primary Myelofibrosis (1) · Respiratory Distress Syndrome (1)
Dompé Farmaceutici S.p.A (12) · Icahn School of Medicine at Mount Sinai (1)
United States (10) · Italy (8) · Germany (4) · Canada (2) · Czechia (2) · Argentina (1) · Australia (1) · Austria (1) · Belarus (1) · Belgium (1) · Brazil (1) · France (1) · Poland (1) · Russia (1) · Spain (1)
Aaron Gerds, MD, MS (1) · Alberto Zangrillo, MD PhD (1) · Barbara Ludwig, MD (1) · Enrico Minnella, MD (1) · Giovanni Landoni, MD (1) · Giovanni Landoni, MD, PhD (1) · Lorenzo Piemonti, MD (1) · Lorenzo Piemonti, MD PhD (1)
PMID 39735417, PMID 40028879, PMID 40318595, PMID 23912763, PMID 28539464, PMID 31924241, PMID 32019854, PMID 33908301, PMID 34476645, PMID 35618953, PMID 37798468, PMID 37972723
2014 (1)